Genmab A/S (Nasdaq: GMAB) – In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in ...

Genmab (GMAB) stock was downgraded by Bernstein due to a looming patent cliff for Darzalex, a blood cancer drug marketed by ...

We recently published a list of 8 Most Undervalued Healthcare Stocks to Buy According to Analysts. In this article, we are ...

Investing.com -- Bernstein analysts have downgraded Genmab A/S (CSE: GMAB) to an "underperform" rating from "market perform,” in a note dated Tuesday. Shares of the Danish biotechnology company were ...

Genmab A/S announced today that the European Commission (EC) has granted marketing authorization for TIVDAK® (tisotumab vedotin), an antibody-drug conjugate (ADC), as monotherapy treatment for adult ...

Genmab (GMAB) announced that the European Commission has granted marketing authorization for TIVDAK, an antibody-drug conjugate, as monotherapy ...

Genmab's Tivdak wins Japan's approval for advanced cervical cancer after a Phase 3 trial showed improved survival over chemotherapy.

Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 3 undervalued ...

Envestnet Portfolio Solutions Inc. reduced its holdings in Genmab A/S (NASDAQ:GMAB – Free Report) by 29.3% in the 4th quarter, according to the company in its most recent 13F filing with the ...

The general mood among these heavyweight investors is divided, with 25% leaning bullish and 62% bearish. Among these notable ...

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and ...

Genmab denies the accusation that it knowingly stole confidential information in a $1.8 billion deal to acquire a cancer drug ...